ERBB2 and gastric cancer: Herein, we collected FFPE tissues of 206 patients with GC before the initiation of different treatments (including DOS, XELOX, and anti-HER2-based therapy), and presented an unprecedented large-scale clinical proteomic landscape, with the aim of identifying reliable predictive markers of the GC patient response to the diverse chemotherapies and targeted therapies.